BTG and Biocompatibles complete sales negotiations
BTG hopes to become an international specialist in the healthcare industry.
BTG and Biocompatibles have come to a deal over their sales negotiations, it has been announced.
The respective international specialist pharmaceutical firm and medical technology enterprise, will combine so that BTG will acquire the entire issued and be issued share capital of Biocompatibles.
According to the firm, the BTG board sees the deal as an opportunity to merge the specialised niche markets with a proven big-sales supplier in order to create "a fast-growing, financially stronger, international specialist healthcare business".
Altogether, the Biocompatibles Fully Diluted Share Capital price stands at approximately £177.2 million.
It was previously speculated by the Thomson Reuters and Freeman Consulting Service survey that worldwide mergers and acquisitions are expected to rise by over a third next year to $3.04 trillion (£1.89 trillion).
Moreover, this represents the highest amount recorded since the pre banking crisis and credit crunch figure of $4.28 trillion in 2007.